-+ 0.00%
-+ 0.00%
-+ 0.00%

Zentalis presents azenosertib preclinical TNBC combination data at AACR 2026

PUBT·04/17/2026 19:11:43
Listen to the news
Zentalis presents azenosertib preclinical TNBC combination data at AACR 2026
  • Zentalis disclosed new preclinical findings for WEE1 inhibitor azenosertib in triple-negative breast cancer, with results scheduled for presentation at AACR 2026 in San Diego on April 20.
  • Data showed azenosertib produced strong anti-tumor activity in models of triple-negative breast cancer, including settings resistant to newer antibody-drug conjugate therapies.
  • Separate real-world analysis of ovarian cancer outcomes will be presented at AACR on April 19, highlighting poorer prognosis for Cyclin E1-positive patients under current standard treatments.
  • Findings support Zentalis strategy to expand azenosertib beyond ovarian cancer while reinforcing its biomarker-driven focus in Cyclin E1-positive ovarian cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001725160-26-000020), on April 17, 2026, and is solely responsible for the information contained therein.